on the call this AM, they basically said that the right answer is somehwere in between quarterly and monthly, dpending on the specific patients disease. Also, interesting that there were zero CV events.
I don't think DNA will even try to convince the docs to go quarterly. This is good news for OSIP and great news for REGN. Just picked up some more REGN on this news.
OSIP can try to position Macugen as the low-cost alternative, which IMO will only work with docs who worked with Eyetech on the clinical trials and/or won't try off-label Avastin.
Market Data 
Markets 
AI
